

Technology Advisory Committee C Interests Register

Topic: Foslevodopa–foscarnidopa for treating advanced Parkinson’s with motor symptoms [ID3876]

Publication Date: 29 November 2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Michael Chambers	Committee Member	Indirect - financial	Mr Chambers has been funded by comparator company Boehringer Ingelheim to make a series of podcasts on HTA, but these did not consider specific Boehringer Ingelheim products. He has also attended an advisory panel for comparator company Pfizer in an unrelated disease area (prostate cancer).	17.04.2023	It was agreed his declarations would not prevent Mr Chambers from participating in discussions for this appraisal.
Dr Steven Lloyd	Committee Member	Indirect – financial, and non-financial professional interests	Dr Lloyd has undertaken advisory work for the manufacturer AbbVie and comparator company Pfizer in unrelated areas around vaccinations and women’s health. Dr Lloyd has received remuneration from AbbVie for work on immunology referral pathways.	22.08.2023 08.09.2023	It was agreed that Dr Lloyd's declarations would not prevent him from participating in discussions on this appraisal.
Dr Richard Nicholas	Committee Member	Non-Financial Professional interests	Dr Nicholas co-direct a Tissue Bank studying multiple sclerosis and Parkinson’s disease at Imperial College which he ran the MS part of. The Tissue Bank is funded from a grant equally by the UK MS Society and PD-UK. Dr Nicholas has no funding from the grant, he is NHS funded.	08.09.2023	It was agreed that Dr Nicholas' declaration would not prevent him from participating in discussions on this appraisal.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Dr Camille Carroll	Clinical expert	Direct - financial & non-financial	Dr Carroll's employer, The University of Plymouth Enterprise Ltd, has received honoraria from AbbVie for advisory boards which Dr Carroll attended in October and November 2021.	04.05.2022	It was agreed her declarations would not prevent Dr Carroll from providing expert advice to the committee.
			Dr Carroll is a local principal investigator in the 741 and 737 clinical trials of this treatment. She is a co-author on conference presentations related to evaluation of this treatment and submitted publications.		
			Dr Carroll received remuneration from AbbVie for providing clinical opinion at the technical engagement stage of this appraisal.	28.04.2023	
			Dr Carroll has received honoraria from comparator company Bial Pharma.	07.09.2023	
Marc van Grieken	Patient expert	Direct - financial	Mr van Grieken is a member of comparator company UCB Pharma's Patient Engagement Council for Parkinson's Research and a member of the Servier Saclay Patient Advisory Board UK and has received remuneration for his input into both.	03.05.2022	It was agreed his declarations would not prevent Mr van Grieken from providing expert advice to the committee.